In a first procedural move of its kind, NCI asked its Board of Scientific Advisors to endorse the institute’s continuing affiliation with the Frederick National Laboratory for Cancer Research, a Federally Funded Research and Development Center.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
